Rotavirus Vaccine, Live, Oral, Pentavalent Articles

2010 Prix Galien winners include Merck & Co, Novartis, Amgen and Bayer

6 April 2011

Europe’s CHMP gives negative opinion for Merck KGaA’ cladribine in multiple sclerosis; backs Sanofi Pasteur MSD’s RotaTeq and GSK’s Rotarix

24 September 2010

Europe’s CHMP recommends approval of Boehringer Ingelheim’s Twynsta and Teva’s generic Plavix; updates on rotavirus vaccines

26 July 2010

Europe’s CHMP adopts opinions on Allergan’s Ozurdex and generic leflunomide and use extensions; proposes Zeffix restriction; backs rotavirus vaccine use

24 May 2010

Amgen files for second US approval of bone drug denosumab, aiming for cancer patient market; FDA backs rotavirus vaccines

17 May 2010

US Coalition for Vaccine Safety calls on FDA to immediately suspend all contaminated rotavirus vaccines

11 May 2010

US FDA advisory committee says rotavirus vaccine benefits outweigh risks; agency accepts Novartis’ sBLA for Menveo

10 May 2010

US FDA recommends temporary suspension of GlaxoSmithKline’s Rotarix due to extraneous virus

23 March 2010

Merck & Co 1st-qtr profit slumps 57%

21 April 2009

2007 Vioxx settlement sees Merck & Co 2008 profit up, despite lower sales

9 February 2009

Rotateq reduces rotavirus-related ER visits 100%

3 November 2008

Rotateq wins WHO pre-qualification status

20 October 2008

SP MSD's rotavirus vacc winning fight?

21 July 2008

Sanofi presents new data on Rotavirus vacc

7 July 2008

RotaTeq "100% effective from first dose"

19 May 2008

High-price vaccines spark four-fold incease in pediatric and adolescent sector

19 November 2007

Austria funds routine rotavirus vaccination of infants

6 August 2007

Merck & Co's 2nd-qtr 2007 EPS jumps 12%

30 July 2007

Rotateq/Gardasil on all US VFC programs

23 July 2007

Merck & Co's 1st-qtr income climbs 12%

30 April 2007

Rise in vaccine costs "put children at risk"

23 April 2007

Jamaica adds RotaTeq to child vacc program

16 April 2007

Reported intussusception cases with RotaTeq "within expected range;" CDC

26 March 2007

US CDC and the WHO reaffirm their support for continued use of Merck & Co's RotaTeq

26 February 2007

FDA warns of risks with Merck & Co's RotaTeq

19 February 2007

Merck & Co predicts more NDA filings in 2007 and highlights strong drug pipeline

22 December 2006

Merck & Co's reaffirms cautious 2006 EPS

18 December 2006

RotaTeq demo program in Venezuela

9 October 2006

Little growth expected in US vaccine R&D for the rest of decade, reports Tufts

14 August 2006

Merck and Co's 2nd-qtr 2006 net income reaches $1.4B thanks to Zocor and Singulair

31 July 2006

Sanofi Pastur's RotaTeq granted postitive opinion by CHMP

8 May 2006

Merck & Co's Rotateq enters US vacc program

27 February 2006

Merck & Co's Rotateq gets FDA OK

13 February 2006

RotaTeq prevents 98% of severe rotavirus gastroenteritis

9 January 2006

Merck and PATH agree rotavirus vaccine deal

19 December 2005

Merck & Co's first taste of life after Vioxx; earnings per share to take substantial hit

20 December 2004

Showing 1-36 of 36 articles

Go to beginningPrevious
  • 1
NextGo to end